CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alopexx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alopexx Inc
186 Alewife Brook Pkwy #1068
Phone: (617) 780-1598p:617 780-1598 CAMBRIDGE, MA  02138  United States Fax: (302) 636-5454f:302 636-5454

Business Summary
Alopexx Inc is a United States-based clinical-stage biotechnology company. The Company is engaged in developing immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). Its immune therapeutics target the conserved microbial surface polysaccharide poly N-acetyl glucosamine (PNAG). The Company's vaccine candidate, Vaccine AV0328, is a synthetic PNAG vaccine. It induces antibodies that are capable of killing a wide range of PNAG-expressing pathogens. AV0328 be developed as a complement to Streptococcus pneumonia vaccines (Prevnar, Pneumovax, and Vaxneuvance). AV0328 could protect against many of approximately 80 serotypes. Its Monoclonal antibody F598 is a human monoclonal antibody.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2021-Yes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder Daniel R.Vlock 70 1/1/2022
Co-Founder Gerald B.Pier 71 1/1/2022
Chief Financial Officer Thomas T.Thomas 65 8/30/2021 8/30/2021
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 7,847,178 (As of 9/7/2022)
Stock Exchange: NASD
Federal Tax Id: 863959763
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 24, 2024